BW
CRL icon

Basepoint Wealth’s Charles River Laboratories CRL Stock Holding History

Basepoint Wealth’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.21K Buy
36
+16
+80% +$2.97K ﹤0.01% 460
2025
Q4 		$3.99K Buy
+20
New +$3.63K ﹤0.01% 477

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Basepoint Wealth's CRL Position: Q1 2026 in Review

Basepoint Wealth increased its Charles River Laboratories (CRL) stake by 80% in Q1 2026, buying an estimated $2.97K and bringing the position to 36 shares worth $6.21K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Basepoint Wealth first reported a position in CRL in Q4 2025 and has held it in 2 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Basepoint Wealth held 36 shares of Charles River Laboratories worth $6.21K as of Q1 2026.
  • Basepoint Wealth bought 16 Charles River Laboratories shares in Q1 2026, an estimated $2.97K.
  • Charles River Laboratories made up ﹤0.01% of Basepoint Wealth's portfolio in Q1 2026, its #460 holding.
  • Basepoint Wealth first reported a position in Charles River Laboratories in Q4 2025 and has held it in 2 quarters since.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.